Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Gloria Crawford"'
Autor:
Anthony D. Elias, Nicole S. Spoelstra, Alyse W. Staley, Sharon Sams, Lyndsey S. Crump, Gregory A. Vidal, Virginia F. Borges, Peter Kabos, Jennifer R. Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadden, Gloria Crawford, Angelo D’Alessandro, Kathryn L. Zolman, Adrie van Bokhoven, Yonghua Zhuang, Rosa I. Gallagher, Julia D. Wulfkuhle, Emanuel F. Petricoin III, Dexiang Gao, Jennifer K. Richer
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract This clinical trial combined fulvestrant with the anti-androgen enzalutamide in women with metastatic ER+/HER2− breast cancer (BC). Eligible patients were women with ECOG 0–2, ER+/HER2− measurable or evaluable metastatic BC. Prior fulv
Externí odkaz:
https://doaj.org/article/ad0c82b5d82a4e81a6170a0a923d1435
Autor:
Jennifer Richer, Nicole Spoelstra, Alyse Winchester, Julia Wulfkuhlue, Rosa Gallagher, Sharon Sams, Gregory Vidal, Peter Kabos, Jennifer Diamond, Elena Shagisultanova, Anosheh Afghahi, Jose Mayordomo, Tessa McSpadded, Gloria Crawford, Virginia Borges, Dexiang Gao, Emanuel Petricoin, Anthony Elias
Publikováno v:
Cancer Research. 82:P1-17
Background: The clinical implications of the androgen receptor (AR), particularly in the context of aromatase inhibitor (AI) refractory metastatic breast cancer (MBC), are unclear. While AR is associated with more indolent primary tumors, in the abse
Autor:
Dexiang Gao, Tessa McSpadden, Sharon Sams, Anthony D. Elias, Virginia F. Borges, Julia Wulfkuhle, Anosheh Afghahi, Emanuel F. Petricoin, Jose I. Mayordomo, Stephanie Armstead, Jennifer R. Diamond, Nicole Spoelsta, Gregory A. Vidal, Elena Shagisultanova, Peter Kabos, Jennifer K. Richer, Lisa Carter, Monica Fournier, Gloria Crawford, Alyse Winchester, Kathryn Zolman
Publikováno v:
Cancer Research. 81:PS12-06
Background: Almost all ER+ breast cancers express androgen receptor (AR), but its function is uncertain. AR expression is associated with more indolent tumors, however high AR expression relative to ER is associated with endocrine resistance, and in
Autor:
Jose I. Mayordomo, Gloria Crawford, Virginia F. Borges, Gregory A. Vidal, Alyse Winchester, Kathryn Zolman, Elena Shagisultanova, Stephanie Armstead, Jennifer K. Richer, Lisa Carter, Dexiang Gao, Anosheh Afghahi, Sharon Sams, Emanuel F. Petricoin, Tessa McSpadden, Peter Kabos, Nicole Spoelsta, Anthony D. Elias, Julia Wulfkuhle, Jennifer R. Diamond
Publikováno v:
Cancer Research. 81:PS12-14
Up to 91% of ER+ breast cancers express androgen receptor (AR), but its function is uncertain. Although AR expression is associated with more indolent tumors, high AR expression relative to ER is associated with endocrine resistance, and in the absen
Autor:
Gloria Crawford, Julia D. Wulfkuhle, Tessa McSpadden, Gregory A. Vidal, Jennifer K. Richer, Sharon Sams, Elena Shagisultanova, Anosheh Afghahi, Jose I. Mayordomo, Virginia F. Borges, Dexiang Gao, Nicole S. Spoelstra, Alyse Winchester, Peter Kabos, Emanuel F. Petricoin, Anthony D. Elias, Jennifer R. Diamond
Publikováno v:
Cancer Research. 81:2867-2867
Background: The clinical implications of the androgen receptor (AR), particularly in the context of aromatase inhibitor (AI) refractory metastatic breast cancer (MBC) are unclear. While AR is associated with more indolent primary tumors, high AR rela
Autor:
Paige, Gloria Crawford
Publikováno v:
Journal of Instructional Psychology. Mar92, Vol. 19 Issue 1, p29. 12p. 5 Charts.